OrchestratePharma GmbH signs agreement with DRPx drug discovery company Cellix Bioscience Pte Ltd for clinical development of topical dermal formulation OP2101. We will commence PK studies prior phase 1 trials.

Cellix Bio Pharma has spent the last five years developing a knowledge pipeline that pulls the data from various organized and amorphous data sources and curates and normalizes this knowledge via a data fabric. OrchestratePharma team partners with DRPx inventors for untrapping value of known molecular entities for delivering approved patient therapies.

Both companies are passionate about contributing to social value and improve the lives of patients around the world.

OP2101 targets CSU (Chronis Spontaneous Urticaria) as second-line treatment. With over 60% of patients remaining symptomatic despite treatment with second generation H1-antihistamines, there is an unmet need for an efficient, safe, and easily accessible medication for CSU patients. OP2101 is intended to fill the gap to current second-line treatments with systemic steroids, cyclosporine and injections with monoclonal antibodies. It is envisaged to be prescribed in primary care as well as by specialists in dermatology and allergology.

‍